Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | METAP1 | P53582 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | MMP14 | P50281 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Boric Acid SCHEMBL28001766 | 0.74 | SMN1; SMN2 (0.47) | LMNAKDM4EHSP90AA1MAPTMETAP2 | |
| SCHEMBL29953696 | 0.74 | ALDH1A1 (0.45) | LMNAKDM4EHSP90AA1MAPTMETAP2 | |
| SCHEMBL29091457 | 0.74 | ALDH1A1 (0.45) | LMNAKDM4EHSP90AA1MAPTMETAP2 | |
| SCHEMBL29232877 | 0.74 | ENPP2 (0.37) | LMNAKDM4EHSP90AA1MAPTSMN1; SMN2 | |
| SCHEMBL2108200 | 0.73 | NOS3 (0.46) | LMNAKDM4EHSP90AA1MAPTMETAP2 | |
| SCHEMBL3563575 | 0.73 | TRIM24 (0.38) | LMNAKDM4EHSP90AA1MAPTSMN1; SMN2 | |
| SCHEMBL29953457 | 0.73 | KDM4E (0.38) | KDM4EMAPTHTTL3MBTL1NFE2L2 | |
| SCHEMBL290645 | 0.73 | KDM4E (0.38) | KDM4EMAPTHTTL3MBTL1NFE2L2 | |
| SCHEMBL729391 | 0.73 | HSP90AA1 (0.38) | LMNAKDM4EHSP90AA1MAPTSMN1; SMN2 | |
| SCHEMBL29517081 | 0.73 | HSP90AA1 (0.38) | LMNAKDM4EHSP90AA1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3519409-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING HIV INFECTION | GILEAD SCIENCES INC (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-110526926-B | Nitrogen-doped material and application thereof | 北京鼎材科技有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20210078991-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10800772-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3519409-A1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING HIV INFECTION | Gilead Sciences, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10138225-B2 | Amide compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-2283024-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2011-02-16 | — | — | EP | disclosed |
| US-20110009404-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-13 | — | — | US | disclosed |
| WO-2010017260-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2009112439-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES AS PLK KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-17 | — | — | WO | disclosed |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-1991544-A2 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS | Transtech Pharma, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1871762-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007089857-A2 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS PTPASE INHIBITORS | TRANSTECH PHARMA, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006113704-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800772-B2 | Therapeutic compounds | NQO1, HAVCR2, CCR5 | LMNA 4094/4885KDM4E 4115/4885HSP90AA1 1954/4885 |
| US-10138225-B2 | Amide compounds for treatment of medical disorders | CFD, TFPI, CFH | LMNA 1604/4885KDM4E 3967/4885HSP90AA1 3629/4885 |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | LMNA 3654/4885KDM4E 212/4885HSP90AA1 4720/4885 |
| US-10005802-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, CFH | LMNA 2178/4885KDM4E 3978/4885HSP90AA1 4295/4885 |
| US-10428094-B2 | Amide compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | LMNA 2004/4885KDM4E 4301/4885HSP90AA1 4128/4885 |
| US-20110009404-A1 | 4-ARYL-2-ANILINO-PYRIMIDINES | PLK4, PLK3, PLK2 | LMNA 334/4885KDM4E 1845/4885HSP90AA1 4454/4885 |
| US-20210078991-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | LMNA 4094/4885KDM4E 4115/4885HSP90AA1 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.